Mutational status of KIT and PDGFRA and expression of PDGFRA are not associated with prognosis after curative resection of primary Gastrointestinal Stromal Tumors (GISTs)

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Alexander Kern - , Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie (Autor:in)
  • Heike Görgens - , Abteilung Chirurgische Forschung (Autor:in)
  • Dag Daniel Dittert - , Institut für Pathologie (Autor:in)
  • Stefan Krüger - , Gemeinschaftspraxis für Humangenetik, Abteilung Chirurgische Forschung (Autor:in)
  • Konrad Klaus Richter - , Southland District Health Board (Autor:in)
  • Hans K. Schackert - , Abteilung Chirurgische Forschung (Autor:in)
  • Hans Detlev Saeger - , Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie (Autor:in)
  • Gustavo Baretton - , Institut für Pathologie (Autor:in)
  • Steffen Pistorius - , Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie (Autor:in)

Abstract

Background: The aim of this study was to investigate if immunohistochemical expression and mutational status of KIT and PDGFRA in GISTs are associated with the clinical course and disease-free survival after curative resection of the primary tumor without adjuvant systemic therapy. Methods: Paraffin-embedded tumor sections of 95 GISTs were analyzed for KIT and PDGFRA expression by immunohistochemistry. PDGFRA expression was judged using a scoring system subdividing tumors in negative/weak and strong immunoreactivity groups. For mutation analysis, exons 9, 10, 11, 13, and 17 of KIT and exons 10, 12, 14, and 18 of PDGFRA were sequenced. Results: Of 95 R0-resected GISTs, 69% showed strong PDGFRA immunoreactivity. Gastric GISTs revealed a significantly higher rate of strong PDGFRA immunoreactivity (P = 0.01) and longer DFS (P = 0.015) than GISTs of the small intestine. KIT mutations were detected in 43 of 63 (68.3%) completely sequenced cases while PDGFRA mutations were identified in 6 cases (10%). In multivariate analysis, neither KIT/PDGFRA expression nor mutational status of KIT or PDGFRA were independent prognostic factors. Only mitotic rate predicted recurrence independently. Conclusion: Our data do not support the notion that expression of PDGFRA or mutations in KIT or PDGFRA are independent prognostic factors after curative resection of primary GIST.

Details

OriginalspracheEnglisch
Seiten (von - bis)59-65
Seitenumfang7
FachzeitschriftJournal of surgical oncology
Jahrgang104
Ausgabenummer1
PublikationsstatusVeröffentlicht - 1 Juli 2011
Peer-Review-StatusJa

Externe IDs

PubMed 21387320

Schlagworte

ASJC Scopus Sachgebiete

Schlagwörter

  • Disease-free survival, GIST, KIT, Mutation analysis, PDGFRA